June 8, 2022
Life Sciences
  • The Food and Drug Administration’s (FDA) vaccine advisory panel voted to authorize Novavax’s COVID-19 vaccine for use in adults. The panel voted 21-0, with one abstention. Novavax’s two-dose vaccine was about 90 percent effective at preventing mild, moderate, and severe COVID-19 during clinical trials. If the FDA gives the green light, Novavax plans to seek authorization as a booster in adults as well as in adolescents and children. (Articles here, here, here, here, and here)